CREDIT SUISSE NEW ISSUE: 6 American Call Warrants on Vifor Pharma Freitag, 19. November 2021 - 09:25
Dear Investor
Please find hereafter the details for these new issues:
Ticker | Valor | ISIN | Underlying | Spot | Strike | Ratio | Maturity | Type | Issue price | Impl. Vola | PDF File |
AVIFCS | 11 485 0144 | CH 114 850 144 3 | Vifor Pharma AG | CHF 120.00 | CHF 120.00 | 50:1 | 17.06.2022 | Call | CHF 0.18 | 25.92% | |
BVIFCS | 11 485 0145 | CH 114 850 145 0 | Vifor Pharma AG | CHF 120.00 | CHF 130.00 | 50:1 | 17.06.2022 | Call | CHF 0.10 | 25.08% | |
CVIFCS | 11 485 0146 | CH 114 850 146 8 | Vifor Pharma AG | CHF 120.00 | CHF 140.00 | 50:1 | 17.06.2022 | Call | CHF 0.06 | 24.85% | |
DVIFCS | 11 485 0147 | CH 114 850 147 6 | Vifor Pharma AG | CHF 120.00 | CHF 120.00 | 50:1 | 16.12.2022 | Call | CHF 0.25 | 26.29% | |
EVIFCS | 11 485 0148 | CH 114 850 148 4 | Vifor Pharma AG | CHF 120.00 | CHF 130.00 | 50:1 | 16.12.2022 | Call | CHF 0.17 | 25.59% | |
FVIFCS | 11 485 0149 | CH 114 850 149 2 | Vifor Pharma AG | CHF 120.00 | CHF 140.00 | 50:1 | 16.12.2022 | Call | CHF 0.11 | 25.18% |
Please visit our website http://www.credit-suisse.com/derivatives to see the complete list of our products.
The warrants will be placed directly in the secondary market. Please call 044/335 76 00.
Kind regards
CREDIT SUISSE AG
Investment Banking
Equity Derivatives & Structured Products
Uetlibergstrasse 231
8070 Zürich, Switzerland
Tel: +41 44 - 335 76 00
Fax: +41 44 - 333 78 08
www.credit-suisse.com
This message may contain confidential, proprietary or legally privileged information and is intended only for the use of the addressee named above. No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this message you are hereby notified that you must not use, disseminate, copy it in any form or take any action in reliance on it. If you have received this message in error please delete it and any copies of it and notify the sender immediately. Credit Suisse Group and its subsidiaries reserve the right to intercept and monitor any e-mail communication through its networks if legally allowed.